OTHER INFORMATION. 
+Added: During the period covered by this Quarterly Report, none of the Company’s directors or executive officers has adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
+Added: 2015 Stock Plan of Moleculin Biotech, Inc.
+Added: as amended, and forms of award agreements thereunder (incorporated by reference to exhibit 4.5 of the Form S-8 file number 333-272814)
Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
12 unchanged sentences
* Filed herewith.
+Added: + The certifications on Exhibit 32 hereto are deemed not “filed”
+Added: for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section.
+Added: Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MOLECULIN BIOTECH, INC.
+Added: August 10, 2023
/s/ Walter V.
1 unchanged sentence
(Principal Executive Officer)
+Added: August 10, 2023
/s/ Jonathan P.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.